HCV Medication Receipt Among Individuals With Methamphetamine, Opioid, and Alcohol Use Disorders in Arkansas, 2018–2022: A Long Road Ahead for HCV Elimination in the US South

Background. Methamphetamine and opioid use disorders (MUD/OUD) are increasing in the US, paralleled by a surge in hepatitis C virus (HCV). HCV is curable with direct-acting antiviral medication (DAA), but people with HCV who use drugs often don’t receive it. We estimated differences in DAA by substa...

Ausführliche Beschreibung

Gespeichert in:  
Bibliographische Detailangaben
1. VerfasserIn: Pro, George (VerfasserIn)
Beteiligte: Hayes, Corey ; Bona, Jonathan ; Gu, Mofan ; Richoux, Camille ; Zaller, Nickolas
Medienart: Elektronisch Aufsatz
Sprache:Englisch
Veröffentlicht: 2025
In: Journal of drug issues
Jahr: 2025, Band: 55, Heft: 3, Seiten: 434-449
Online-Zugang: Volltext (lizenzpflichtig)
Journals Online & Print:
Lade...
Verfügbarkeit prüfen: HBZ Gateway
Schlagwörter:
Underserved populations
Substance Abuse
infectious disease
health service research
claims analysis

MARC

LEADER 00000naa a22000002c 4500
001 1929300654
003 DE-627
005 20250628054812.0
007 cr uuu---uuuuu
008 250628s2025 xx |||||o 00| ||eng c
024 7 |a 10.1177/00220426241231720  |2 doi 
035 |a (DE-627)1929300654 
035 |a (DE-599)KXP1929300654 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 2,1  |2 ssgn 
100 1 |a Pro, George  |e VerfasserIn  |0 (orcid)0000-0001-8901-9012  |4 aut 
245 1 0 |a HCV Medication Receipt Among Individuals With Methamphetamine, Opioid, and Alcohol Use Disorders in Arkansas, 2018–2022: A Long Road Ahead for HCV Elimination in the US South 
264 1 |c 2025 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Background. Methamphetamine and opioid use disorders (MUD/OUD) are increasing in the US, paralleled by a surge in hepatitis C virus (HCV). HCV is curable with direct-acting antiviral medication (DAA), but people with HCV who use drugs often don’t receive it. We estimated differences in DAA by substance type among people with HCV in Arkansas. Methods. We used a statewide medical claims database to identify HCV cases who also had MUD, OUD, and/or AUD (pooled 2018–2022; N = 5439). We used multiple logistic regression to model DAA receipt, adjusted for relevant covariates. Results. Only 10% of our sample received DAA. The lowest predicted probabilities of DAA receipt were among people who used methamphetamine (4.5%) and those covered by Medicaid (5.4%). Conclusion. Arkansas Medicaid has the strictest requirements for initiating DAA in the country. Public health efforts that reduce exposure to HCV among people who use drugs will reduce the HCV burden in Arkansas. 
650 4 |a Underserved populations 
650 4 |a Substance Abuse 
650 4 |a infectious disease 
650 4 |a health service research 
650 4 |a claims analysis 
700 1 |a Hayes, Corey  |e VerfasserIn  |4 aut 
700 1 |a Bona, Jonathan  |e VerfasserIn  |4 aut 
700 1 |a Gu, Mofan  |e VerfasserIn  |4 aut 
700 1 |a Richoux, Camille  |e VerfasserIn  |4 aut 
700 1 |a Zaller, Nickolas  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of drug issues  |d Thousand Oaks, Calif. : Sage, 1971  |g 55(2025), 3, Seite 434-449  |h Online-Ressource  |w (DE-627)331258277  |w (DE-600)2051257-0  |w (DE-576)260774243  |x 1945-1369  |7 nnas 
773 1 8 |g volume:55  |g year:2025  |g number:3  |g pages:434-449 
856 4 0 |u https://doi.org/10.1177/00220426241231720  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
935 |a mkri 
951 |a AR 
ELC |a 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4739405040 
LOK |0 003 DE-627 
LOK |0 004 1929300654 
LOK |0 005 20250628043607 
LOK |0 008 250628||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-2619)KrimDok#2025-06-27#84CD4DAC324740AFD025ED7623CB2CE62CBCF11A 
LOK |0 040   |a DE-2619  |c DE-627  |d DE-2619 
LOK |0 092   |o n 
LOK |0 852   |a DE-2619 
LOK |0 852 1  |9 00 
LOK |0 935   |a zota 
ORI |a WA-MARC-krimdoka001.raw